Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Can Fite Biopharma's share price for the quarter that ended in Dec. 2025 was $4. Can Fite Biopharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 1.31 Mil. Therefore, Can Fite Biopharma's market cap for the quarter that ended in Dec. 2025 was $5.24 Mil.
Can Fite Biopharma's quarterly market cap
declined
from Dec. 2024 ($16.15 Mil) to Jun. 2025 ($13.88 Mil) and
declined
from Jun. 2025 ($13.88 Mil) to Dec. 2025 ($5.24 Mil).
Can Fite Biopharma's annual market cap
increased
from Dec. 2023 ($9.99 Mil) to Dec. 2024 ($16.15 Mil) but then
declined
from Dec. 2024 ($16.15 Mil) to Dec. 2025 ($5.24 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Can Fite Biopharma's Enterprise Value for Today is $-1.68 Mil.
Can Fite Biopharma (AMEX:CANF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Can Fite Biopharma Market Cap Related Terms
Can Fite Biopharma Market Cap Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Can Fite Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Can Fite Biopharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma (CANF) has a Market Cap of $6.79 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Can Fite Biopharma and its competitors. According to the industry distribution chart, Can Fite Biopharma ranks #1261 out of 1431 companies in the Biotechnology industry, placing it in the top 88.1%.
Is Can Fite Biopharma's Market Cap too high?
Can Fite Biopharma's current Market Cap is $6.79 Mil. The Biotechnology industry median Market Cap is 117.63. Can Fite Biopharma's value of $6.79 Mil is 94.2% below this industry median. Based on the distribution chart, Can Fite Biopharma ranks #1261 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #1261 out of 1431 companies for Market Cap. This places Can Fite Biopharma in the lower half of its industry. The industry median Market Cap is 117.63. Can Fite Biopharma's value of $6.79 Mil is 94.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Can Fite Biopharma's current Market Cap of $6.79 Mil is 94.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Can Fite Biopharma and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current Market Cap is $6.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.98, compared to a current price of $2.99 — trading 50% below its estimated fair value. The current Market Cap is $6.79 Mil and 94.2% below the Biotechnology industry median of 117.63. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Market Cap is $6.79 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $2.99 is trading 50% below its estimated GF Value™ of $5.98.
GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.
Key valuation signals for CANF:
Market Cap: $6.79 Mil
GF Value™: $5.98 vs. price of $2.99 (50% below fair value)
Industry Position: 94.2% below the Biotechnology median (#1261 of 1431)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score
Get the complete analysis for CANF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
